Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte‐colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study-Reference-Cited by-同舟云学术

Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte‐colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study

Published:2021-02-15 Issue:8 Volume:12 Page:1154-1161
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Liu Chang¹^ORCID,Hao Ying¹,Wang Lei¹²,Meng Fanlu¹,Wen Fuyu¹,Zhong Diansheng¹^ORCID

Affiliation:

1. Tianjin Medical University General Hospital Tianjin China

2. Tianjin Chest Hospital Tianjin China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13883

Reference28 articles.

1. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor

2. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims

3. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC)

4. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations

5. Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Compression Analysis for BlueField-2/3 DPUs: Lossy and Lossless Perspectives;IEEE Micro;2024

2. Progress of Clinical Application of Pegylated Recombinant Human Granulocyte-Colony Stimulating Factors and Its Effect on Immune Status;Advances in Clinical Medicine;2022

3. Cisplatin/etoposide;Reactions Weekly;2021-11

4. Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte‐colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study;Thoracic Cancer;2021-02-15